Combination of BA-210 and digestion of the glial scar in chronic spinal cord injury

BA-210 与慢性脊髓损伤中胶质疤痕消化的结合

• 批准号: 8832809
• 负责人: Lisa J McKerracher
• 金额: $ 31.92万
• 依托单位: BIOAXONE BIOSCIENCES, INC.
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-03-01 至 2017-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8832809
• 关键词: Acute; Agglutinins; American; Animals; Antibodies; Arylsulfatase B; Axon; Biological Assay; Blood - brain barrier anatomy; Cervical spinal cord injury; Chondroitin ABC Lyase; Chondroitin Sulfate Proteoglycan; Chronic; Cicatrix; Clinical; Clinical Research; Clinical Treatment; Clinical Trials; Combined Modality Therapy; Corticospinal Tracts; Development; Digestion; Dose; Drug Combinations; Drug Targeting; Effectiveness; Enzyme-Linked Immunosorbent Assay; Enzymes; Epitopes; Evaluation; Functional disorder; GAG Gene; Glial Fibrillary Acidic Protein; Goals; Guanosine Triphosphate Phosphohydrolases; Hand; Histology; Human; Immune response; Injection of therapeutic agent; Investigational Drugs; Label; Lectin; Lesion; Life; Marketing; Measures; Modeling; Monitor; Movement; Mus; Natural regeneration; Nervous System Trauma; Neuraxis; Neurons; Outcome; Paralysed; Patients; Pharmaceutical Preparations; Phase; Pump; Quality of life; Rattus; Recovery; Recovery of Function; Route; Safety; Signal Transduction; Site; Small Business Innovation Research Grant; Sodium Dodecyl Sulfate-PAGE; Spinal Cord; Spinal cord injury; Staining method; Stains; System; Temperature; Testing; Topical application; Wisteria; aggrecan; arm; axon regeneration; collagenase; effective therapy; efficacy testing; functional outcomes; immunocytochemistry; improved; injured; monocyte; mouse model; prevent; public health relevance; repaired; research study; rho; scaffold

DESCRIPTION (provided by applicant): BA-210 is an investigational drug that targets Rho, an intracellular GTPase important for controlling axon regeneration and repair after spinal cord injury. BA-210 has completed a Phase I/IIa clinical trial for treatment of acute spinal cord injury in 48 patients. Not only was BA-210 safe and well tolerated, but patients with cervical SCI showed very promising recovery of arm and hand movements. While current development is to treat acute spinal cord injury, BA-210 has potential to improve outcome in patients with chronic SCI, especially if used in combination with other therapies. One barrier to treating chronic SCI is the glial scar that develops and remains after SCI. Several drugs currently on the market have the potential to digest the glial scar and could be repurposed for SCI. Combining BA-210 with a repurposed drug will accelerate the regulatory path to clinical trials and approval. The overall goal of this SBIR project is to investigate the use of BA-210 in combination with one of two drugs that digest the glial scar as a treatment for chronic SCI.

描述（由申请人提供）：BA-210 是一种针对 Rho 的研究药物，Rho 是一种细胞内 GTP 酶，对于控制脊髓损伤后的轴突再生和修复非常重要。 BA-210已完成治疗急性脊髓损伤的I/IIa期临床试验 48 名患者中。 BA-210 不仅安全且耐受性良好，而且颈椎 SCI 患者的手臂和手部运动恢复也非常有希望。虽然目前的开发是治疗急性脊髓损伤，但 BA-210 有潜力改善慢性 SCI 患者的预后，特别是与其他疗法联合使用时。治疗慢性 SCI 的一大障碍是 SCI 后形成并保留的神经胶质疤痕。目前市场上的几种药物具有消化神经胶质疤痕的潜力，可以重新用于 SCI。将 BA-210 与重新利用的药物相结合将加速临床试验和批准的监管进程。该 SBIR 项目的总体目标是研究 BA-210 与两种消化神经胶质疤痕药物中的一种联合使用来治疗慢性 SCI。